It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Find out which no annual fee cards provide the highest cash back rewards. Choose wisely to maximize your earnings!
26,626 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
When a fund trims Frontier stock, it can signal rebalancing, risk management, or strategic shifts. This article break...
PennyMac’s Third-Party Origination unit rolls out a seven-program non-QM suite to broaden options for borrowers with ...
Micron Technology posted a strong quarter but faced a sharp pullback as investors priced in a tougher near-term path....
A 2025 study finds only 26% of Americans correctly understand Medicare covers about two-thirds of retirees' healthcar...
Stocks climbed as heavyweight tech names posted solid results and ceasefire hopes supported risk appetite, sending th...
Rent is due on the first, but most workers are paid on varied schedules. A growing body of data points to a hidden co...
When a crypto-focused firm makes a substantial equity bet in a media company, it can signal strategic confidence—and ...
Even with a stunning 19x profit surge, Samsung's stock slipped. This article breaks down why the market reacted this ...
Avantis U.S. Small Cap Value ETF relies on a profitability filter that separates it from ordinary small-cap funds, ai...
Rheinmetall posted a quarterly miss that undercut expectations for revenue, net income and margins, triggering a pull...
IBM’s leadership points to a quicker, clearer regulatory path for mergers and acquisitions, citing the Confluent purc...